Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Lupin had earlier received the USFDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim).from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jdsEbam6I
via IFTTT
0 comments:
Post a Comment